Morgan Allen
Family · Anderson, SCNPI 1881157667
Payments from drug & device makers
Across 91 payments — averaging $14.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$295
- AstraZeneca$194
- Bayer$167
- Lilly USA, LLC$118
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$81
- Lundbeck LLC$67
- plus $438 from 14 others
What the payments were for
- Food & beverage$1,359100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $295 |
| AstraZeneca | 9 | $194 |
| Bayer | 21 | $167 |
| Lilly USA, LLC | 7 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $81 |
| Lundbeck LLC | 3 | $67 |
| GSK | 4 | $66 |
| Merck | 3 | $50 |
| Exact Sciences | 3 | $50 |
| Johnson & Johnson | 2 | $37 |
| AbbVie | 2 | $33 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Shield Therapeutics Inc | 2 | $31 |
| Boehringer Ingelheim | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $20 |
| Pfizer | 1 | $19 |
| Novartis | 1 | $18 |
| Medtronic | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
How this compares
$1,359 in reported general payments places this provider in the 70th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 85 | $96,243 |
| OzempicSemaglutide | 57 | $59,305 |
| FarxigaDapagliflozin Propanediol | 21 | $35,321 |
| JardianceEmpagliflozin | 16 | $28,565 |
| EliquisApixaban | 26 | $17,991 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $14,052 |
| XareltoRivaroxaban | 13 | $11,640 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,446 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $9,891 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,891 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 89 | $3,075 |
| Rosuvastatin Calcium | 270 | $2,965 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $2,626 |
| SynthroidLevothyroxine Sodium | 18 | $1,772 |
| Gabapentin | 111 | $1,647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $118 | $96,24385 claims |
| Novo NordiskOzempic | $295 | $59,30557 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $194 | $51,99958 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $28 | $38,45631 claims |
| PfizerEliquis | $19 | $17,99126 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $66 | $17,33725 claims |
| Johnson & JohnsonXarelto | $37 | $11,64013 claims |
| AbbVieSynthroid | $33 | $1,77218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,248 family providers in South Carolina.
Other family in Anderson
- Kara Cooper GilmerAnderson$127K
- Nancy RichmondAnderson$21K
- Margaret KelleyAnderson$12K
- Lisa CobbAnderson$11K
- Sarah HambyAnderson$10K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.